3Greenlee RT, Murray T, Bolden S, et al. Cancer Statistics [J]. CA Cancer J Clin, 2000,50 (1):7-33.
4Feld R, Abratt R, Graziano S, et al. Pretreatment minimal staging and prognostic factors for non small cell hung cancer [J]. Lung Cancer,1997,17(Suppl 1 ):S3-10.
5Graziano SL, Kern JA, Herndon JE, et al . Analysis of neuroendcrine markersHER2 and CEA before and after chemotherapy in patients with stage Ⅲ A non small cell lung cancer: a Cancer and Leukemia Group B study[J]. Lung Cancer, 1997,21 (3) : 203-211.
6Rafael R , Mark G, Paul G. Adervances in the treatment of non-small cell lung cancer: molecular markers take the stage [J]. Sem Oncol, 2001,1 (28)28-34.
7Cullen MH, Billingham, LJ, Woodroffe CM, et al. Mitomycin, ifosfarnide, and cisplatin in unresectable non-small cell lung cancer:effects on survival and quality of life[J]. J Clin Oncol, 1999,17(10):3188-3194.
8Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group [J]. Anticancer Res, 2000, 20 (3B):2229-2233.
9Wozniak A J, Crowley JJ, Ba Lcerzak SP, et al. Randomized trial comparing cixplatin with a splatin plus vinorelbine in the tzeatment of advanced non-small-cell lung cancer:a Southwest Oncology Group Study [J]. J Clin Oncol, 1998,16(7):2459-2465.
10Sandier A,Nemunaitis J,Denham C, et al. Phase Ⅲ trial of gemcitabine plus cisplatin vesus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer [J]. J Clin Oncol,2000, 18(1) : 122-130.
